![](/img/cover-not-exists.png)
An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies
Pivot, X., Poole, C., Martín, M., Gligorov, J., Barrios, C.H., Vrdoljak, E., Gianni, L., Tije, A.J. Ten, Machackova, Z., Truman, M., Steger, G.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw364.66
Date:
October, 2016
File:
PDF, 47 KB
english, 2016